with no apparent disease progression in patients otherwise classified as 'complete remission' added significant stress to patients and their doctors and generated substantial unnecessary testing. Although inconclusive at this point, this group of false positives suffered mostly from chronic inflammatory and/or noninflammatory skin affections (herpetic infections, unhealed defects after radiotherapy with or without secondary bacterial infections and in some the reason was not apparent). In clinical practice the true difference between 'false positivity' and 'lead time' is difficult to distinguish during a limited time period; those markers with lead times longer than 7 months do not prove very useful for influencing patient outcome -this may obviously be the case of some of our 55 patients. It is our belief that the validity of new biomarkers and reevaluation of those used previously (Robertson, 1998) should be critically reassessed on a periodic basis if the ultimate goal is to improve patient care while avoiding unnecessary increases in noise and cost of health care. In agreement with the authors of the present paper, we currently recognize the potential of serum TPS only as a marker for monitoring response to cytotoxic therapy in explicitly defined diagnostic groups and when the potential of administering curative therapy exists, which indeed may include neuroblastoma and Wilms' tumor. In our opinion, TPS should not be used as a diagnostic marker and only in exceptional cases as a marker for disease recurrence. Response to: Serum tissue polypetide-specific antigen (TPS): what is its diagnostic value Ð reply Sir, We are glad that our paper has aroused the interest of Drs Valik and Nekulova and that they can agree with our conclusions regarding the potential of TPS as a tool for monitoring therapy response. However, we would like to make a few comments on this letter.
First of all, our paper did not report clinical experience. The situation in paediatric oncology is very different from adult oncology. Apart from catecholamines and NSE in neuroblastoma (not in Wilms' tumor) there are no 'established' tumour-markers. For TPS we actually had to establish normal values for healthy children (Rebhandl et al, 1997 ) before addressing patients with malignant disease. Furthermore, all our data are based on TPS and not on TPA, which in our opinion is not comparable.
Breast and colorectal cancer are among the most frequent malignant diseases in the western world, while the incidence of DOI: 10.1054 DOI: 10. / bjoc.1999 DOI: 10. .1245 , available online at http://www.idealibrary.com on both neuroblastoma and Wilms' tumour is fortunately low. Large international multicentre studies are usually necessary to obtain sufficient data within an acceptable period.
For these reasons it is quite difficult to compare the applicability of TPS in so entirely different patient groups and different malignancies.
Any tumour marker (and any diagnostic tool) must be weighed against standard diagnostic procedures after exclusion of confounding factors. Again, it is too early to judge whether TPS measurements will become part of the diagnostic routine. In an otherwise healthy child presenting with an abdominal mass it could lead to an earlier diagnosis, especially since biopsy is strictly forbidden in (suspected) Wilms' tumours. ROC analysis enabled us to show good differentiation between benign and malignant disease in our patients.
The hypothesis that TPS could be a marker for apoptosis rather than for proliferation is interesting but it still awaits final experimental proof. TPS, which is a 22 kD fragment of cytokeratin 18 (Rydlander et al, 1996) may indeed correspond to the K18 C fragment described by . Direct testing with the monoclonal antibody should decide this issue.
An activation of caspase-3 during chemo-or radiotherapy should actually lead to an increase in TPS-serum values and not to the significant decline we found in our patients. However, many issues are still undecided in this area, among them the surprising phenomenon that elevated TPS can be found in non-epithelial tumours (Vogl, 1995; . All this points to the fact that degradation of cytokeratin 18 may be a key element of tumour biology.
